Annexure I

Deviation Form

Company Logo Here

XX PHARMACEUTICALS LIMITED 117 Adams Street, Brooklyn, NY 11201, USA

Deviation Form

Deviation Ref No.:

Section A: RECORD OF DEVIATION (To be filled by initiator immediately i.e. 1/2 day of incident)

Deviation No. & Date of Report				Date of incident:		0	
Department				Initiators Name:			
Designation				Signature:			
Time of incident:	Observer:			Witness:			
Source of Deviation (possible source of departure) Put √ at right	SOP		Product/RN Specification			Human error	
	BMR/BPR		Control dire	ection		Validation/ Stability protocol	
	Equipment & Facility		Documenta	ation error		Calibration failure	
	Storage condition		Environmental limit			Reprocess	
	Yield & Reconciliati on		Instruction contract ma	given by anufacturer			
1	Other (specify):						

Page X of Y

Identification of implicated system	Product Name:	Batch No:	
	Material Code:	Equipment/Facility name & identifier:	
	Equipment location:		

Details of event:	
(Generally initiator will define	
the following in details:	
o How was the	
deviation found and by whom?	
o Over what time	
period has the deviation occurred	
o What deviation in	
the process	0°
occurred?	
Provide as much detail as	
possible drawing on the experience of the investigators	71°
assembled.)	

Page X of Y

Immediate (Remedial) Action (Put √ where it is applicable)					
Operat on Suspended		Modification of the process/procedure/Equipment			
Segregation of material		Reject/discard	Adjustment		
Others (specify details):					

Name of person(s) who performed specific remedial ac	tion(s).			
Date of completion of remedial action:				
Signature of Functional Head:	Signature of Functional Head:			Date:
Section B: Assessment of Risk (To be filled by Quality	y Complian	ce Manager &	L Department Manager w	ithin 1 day of incident)
Available Information for impact assessment (Batch Document, Log book, Line clearance any other policy)				
Reference of information:				
Assessment Factors:	Yes	No	Details	
Will impact on strength, identity, purity and stability of the product			lille	
Have effect on both local/USFDA/EU regulatory compliance			9	
Immediate impact on any implicated batches	_			
Possible impact on other batches				
Patient /Customer safety				
Current status of impacted batch				
Detection point of failure (detected by chance/detected during checking/detected at the point of error)				
whether the implicated batch is on the market or within XX's control	□ Yes	□ No		
Any immediate ac ion is required further	□ Yes	□ No		
	Details:			
Prevent manufacture of defective product	□ Yes	□ No		

Prevent defective product to reach market	□ Yes □ No				
Any impact on batch release	□ Yes □ No				
Any other risks (If requires Risk Assessment tool i.e. FMEA will be used for Major/Critical deviation)					
	60.34				
Criticality	□Critical □ Major □ Minor				
Communication with Contract Manufacturer	□ Yes □ No				
Recommendation of Contract Manufacturer	ommendation of Contract Manufacturer				
Quality Compliance Recommendation:					
Target Date: Respo					
Requirement of investigation: No					
Justification (only if investigation is not required):					
Quality Compliance Manager : Date					
SECTION C: INVESTIGATION & IDENTIFICATION OF ROOT CAUSE (Department Manager: Within 15 days)					
Investigation reference No:	Start date : Completed on:				
* Separate Approved Investigation report is to be attached					

SECTION D: CAPA APPROVAL

Requirement of CAPA: No				
If yes, put the CAPA reference No:				
Requirement of any immediate action:				
		JH		
Action	Completed Date	Responsible		
		O		
SECTION E: CLOSING				
Completion of all identified/recommended action	/QA Follow up:			
Release date of impacted batch/Equipment or facility ready to use:				
Signature of Quality Compliance Manager				
CLOSED	Manager, Quality Assurance Date			